Blood test could replace surgery for heart tumor diagnosis
NCT ID NCT07235865
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a blood test, called a liquid biopsy, can accurately diagnose and monitor heart masses (tumors) without needing a surgical biopsy. Researchers will collect blood samples from 26 patients aged 12 and older with suspected or confirmed cardiac masses. They will analyze the blood for tumor DNA and compare results with standard tissue samples. If the blood test works, it could offer a safer, less invasive way to diagnose and track heart tumors over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Liquid biopsy (blood test for ctDNA)
- What this could lead to
- If successful, this could provide a non-invasive way to diagnose and monitor heart tumors, potentially reducing the need for risky biopsies or surgeries.
- What could go wrong
- This is a small, early observational study with only 26 participants. The blood test may not be accurate enough to replace standard diagnostic methods, and results may not apply to all types of cardiac masses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC MASSES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Niguarda Hospital
RECRUITINGMilan, Italia, 20262, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.